Kolexia
Barriere Nicolas Gastro-entérologie
Barriere Nicolas
Gastro-entérologie
Hôpital Européen Marseille
Marseille, France
47 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Tumeurs du côlon Métastase tumorale Tumeurs de l'estomac Tumeurs du foie Fragilité {{person.topmesh8.name}} {{person.topmesh9.name}} {{person.topmesh10.name}}

Collaborateurs

Voir plus
Rinaldi Yves
Rinaldi Yves
Hôpital Européen Marseille, Marseille, France
Gigout Julie
Gigout Julie
Hôpital Européen Marseille, Marseille, France
Julien Cecile
Julien Cecile
Hôpital Européen Marseille, Marseille, France
Camerlo Antoine
Camerlo Antoine
Euromed Cardio, Marseille, France

Industries

Voir plus
Servier
4 collaboration(s)
Dernière en 2023
Ipsen
3 collaboration(s)
Dernière en 2020
Abbvie
3 collaboration(s)
Dernière en 2022
Takeda Pharmaceutical
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
OSCAR: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.
2022 ASCO Annual Meeting I   02 juin 2022
444P PRODIGE 25 (FFCD 11-01)-FOLFA: A randomized phase II trial evaluating aflibercept associated with LV5FU2 regimen as first-line treatment of non-resectable metastatic colorectal cancers
Abstract Book of the ESMO Virtual Congress2020 19 – 21 September / 16 – 18 October 2020   01 septembre 2020
Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19).
2019 ASCO Annual Meeting I   26 mai 2019
Predicting chemotherapy toxicity and death in older adults with colon cancer: Results of MOST (Massilia Oncologic Senior Tests) study.
2018 ASCO Annual Meeting I   01 juin 2018
PRODIGE 25 (FFCD 11-01) - Phase II randomized trial evaluating aflibercept associated with LV5FU2 regimen as first line treatment of non-resectable metastatic colorectal cancers (FOLFA)
Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark   01 octobre 2016
Frailty markers for prediction of mortality in first-line chemotherapy for colon cancer patients: Results of MOST/ASRO 101 study.
2014 ASCO Annual Meeting I   20 mai 2014
{{person.lastact8.name}}
{{person.lastact8.jour}}   {{person.lastact8.date}}
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}